SOURCE: LipidViro Tech, Inc.

March 28, 2007 08:52 ET

LipidViro Tech, Inc. Announces Interview on Market News First at 4:00 PM Today

SALT LAKE CITY, UT -- (MARKET WIRE) -- March 28, 2007 -- LipidViro Tech, Inc. (OTCBB: LPVT), a development-stage medical device company, announced that J. S. Latino, co-founder and Head of Research, is scheduled to be interviewed live today, March 28, 2007, on Market News First, (, at 4:00 PM EDT. Listeners are encouraged to point their browser to at least five minutes before the scheduled interview time.

About LipidViro Tech, Inc.

LipidViro Tech, Inc. is an early-stage biotechnology company engaged in research and commercial development of d-OSAB, a multi-therapeutic device-based platform. The Company's first commercial therapeutics target Ischemic Brain Stroke and Chronic Heart Failure, two diseases with few viable treatment options, and markets exceeding $20 billion annually.

During 2007 LipidViro is scheduled to commence a 100-patient Phase IIa study treating patients who have suffered an ischemic brain stroke. d-OSAB targets the untreated stroke population estimated to approach 99% of individuals afflicted with ischemic stroke residing in the European Union (EU). LipidViro's development and commercialization strategy is to move its controlled-dosage d-OSAB platform for the treatment of stroke through the European Union (EU) regulatory process. Multi-site EU Phase III studies and concurrent pre-application meetings with the FDA will follow positive clinical results from this Phase IIa trial.

Stroke is the second leading cause of death worldwide, responsible for 4.4 million deaths each year. Annually, stroke strikes more than 1.7 million people in the U.S. and EU. Seven percent of ischemic stroke patients die within 30 days, 25% die within one year. More than 50% of surviving patients have permanent disabilities that require nursing home or other long-term care. The single approved therapeutic for ischemic brain stroke patients is tPA. Patients are only eligible for tPA during a three-hour window from time of stroke, use after three hours causes bleeding in the brain which may prove fatal. Consequently, more than 94% of U.S. stroke patients are not eligible for tPA and have no other viable treatment option.

Contact Information